MADHAVBAUG
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
Vaidya Sane Ayurved Laboratories - Madhavbaug Opens First Hospital In Gujarat
Vaidya Sane Ayurved Laboratories Ltd VAID.NS:
VAIDYA SANE AYURVED LABORATORIES - MADHAVBAUG OPENS FIRST HOSPITAL IN GUJARAT
Source text: ID:nNSE70W6dk
Further company coverage: VAID.NS
Vaidya Sane Ayurved Laboratories Ltd VAID.NS:
VAIDYA SANE AYURVED LABORATORIES - MADHAVBAUG OPENS FIRST HOSPITAL IN GUJARAT
Source text: ID:nNSE70W6dk
Further company coverage: VAID.NS
Vaidya Sane Ayurved Laboratories Inked An MoU With Andhra Pradesh Medtech Zone
Sept 26 (Reuters) - Vaidya Sane Ayurved Laboratories Ltd VAID.NS:
VAIDYA SANE AYURVED LABORATORIES LTD - INKED AN MOU WITH ANDHRA PRADESH MEDTECH ZONE
Source text for Eikon: ID:nNSE5Fnxl9
Further company coverage: VAID.NS
(([email protected];))
Sept 26 (Reuters) - Vaidya Sane Ayurved Laboratories Ltd VAID.NS:
VAIDYA SANE AYURVED LABORATORIES LTD - INKED AN MOU WITH ANDHRA PRADESH MEDTECH ZONE
Source text for Eikon: ID:nNSE5Fnxl9
Further company coverage: VAID.NS
(([email protected];))
Vaidya Sane Ayurved Laboratories Appoints Shripad Upasani As CEO
Aug 31 (Reuters) - Vaidya Sane Ayurved Laboratories Ltd VAID.NS:
APPOINTS SHRIPAD UPASANI AS CEO
Source text for Eikon: [ID:]
Further company coverage: VAID.NS
(([email protected];))
Aug 31 (Reuters) - Vaidya Sane Ayurved Laboratories Ltd VAID.NS:
APPOINTS SHRIPAD UPASANI AS CEO
Source text for Eikon: [ID:]
Further company coverage: VAID.NS
(([email protected];))
Vaidya Sane Ayurved Laboratories To Issue Of Share Warrants To Strategic Investors Upto 426.5 Million Rupees
July 11 (Reuters) - Vaidya Sane Ayurved Laboratories Ltd VAID.NS:
APPROVED FUND RAISING THROUGH PREFERENTIAL ISSUE OF SHARE WARRANTS TO STRATEGIC INVESTORS UPTO 426.5 MILLION RUPEES
Source text for Eikon: ID:nNSE9FqpsH
Further company coverage: VAID.NS
(([email protected];))
July 11 (Reuters) - Vaidya Sane Ayurved Laboratories Ltd VAID.NS:
APPROVED FUND RAISING THROUGH PREFERENTIAL ISSUE OF SHARE WARRANTS TO STRATEGIC INVESTORS UPTO 426.5 MILLION RUPEES
Source text for Eikon: ID:nNSE9FqpsH
Further company coverage: VAID.NS
(([email protected];))
Vaidya Sane Ayurved Laboratories Executed Share Purchase Agreement With Shareholders Of Dynamic Remedies And UV Ayurgen Pharma
April 12 (Reuters) - Vaidya Sane Ayurved Laboratories Ltd VAID.NS:
EXECUTED SHARE PURCHASE AGREEMENT WITH SHAREHOLDERS OF DYNAMIC REMEDIES AND UV AYURGEN PHARMA
COST OF ACQUISITION FOR DYNAMIC REMEDIES AT 35 MILLION RUPEES
COST OF ACQUISITION FOR UV AYURGEN PHARMA AT 15 MILLION RUPEES
Source text for Eikon: ID:nNSEVyG1c
Further company coverage: VAID.NS
(([email protected];))
April 12 (Reuters) - Vaidya Sane Ayurved Laboratories Ltd VAID.NS:
EXECUTED SHARE PURCHASE AGREEMENT WITH SHAREHOLDERS OF DYNAMIC REMEDIES AND UV AYURGEN PHARMA
COST OF ACQUISITION FOR DYNAMIC REMEDIES AT 35 MILLION RUPEES
COST OF ACQUISITION FOR UV AYURGEN PHARMA AT 15 MILLION RUPEES
Source text for Eikon: ID:nNSEVyG1c
Further company coverage: VAID.NS
(([email protected];))
Events:
Dividend
Dividend
More Nano Cap Ideas
See similar 'Nano' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Vaidya Sane Ayur Lab do?
Vaidya Sane Ayurved Laboratories Limited in India offers specialized treatment for chronic ailments like cardiac disease, diabetes, hypertension, and obesity using a mix of modern technology and traditional Ayurveda practices.
Who are the competitors of Vaidya Sane Ayur Lab?
Vaidya Sane Ayur Lab major competitors are Lyka Labs, Gennex Lab, Ambalal Sarabhai Ent, Brooks Laboratories, Coral Laboratories, Zim Laboratories, Kimia Biosciences. Market Cap of Vaidya Sane Ayur Lab is ₹251 Crs. While the median market cap of its peers are ₹195 Crs.
Is Vaidya Sane Ayur Lab financially stable compared to its competitors?
Vaidya Sane Ayur Lab seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
Does Vaidya Sane Ayur Lab pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Vaidya Sane Ayur Lab latest dividend payout ratio is 5.44% and 3yr average dividend payout ratio is 5.44%
How has Vaidya Sane Ayur Lab allocated its funds?
Companies resources are allocated to majorly productive assets like Plant & Machinery
How strong is Vaidya Sane Ayur Lab balance sheet?
Balance sheet of Vaidya Sane Ayur Lab is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Vaidya Sane Ayur Lab improving?
The profit is oscillating. The profit of Vaidya Sane Ayur Lab is ₹8.24 Crs for TTM, ₹1.98 Crs for Mar 2024 and ₹4.83 Crs for Mar 2023.
Is the debt of Vaidya Sane Ayur Lab increasing or decreasing?
Yes, The net debt of Vaidya Sane Ayur Lab is increasing. Latest net debt of Vaidya Sane Ayur Lab is -₹4.91 Crs as of Sep-25. This is greater than Mar-24 when it was -₹32.47 Crs.
Is Vaidya Sane Ayur Lab stock expensive?
Vaidya Sane Ayur Lab is not expensive. Latest PE of Vaidya Sane Ayur Lab is 35.22, while 3 year average PE is 56.97. Also latest EV/EBITDA of Vaidya Sane Ayur Lab is 11.12 while 3yr average is 13.44.
Has the share price of Vaidya Sane Ayur Lab grown faster than its competition?
Vaidya Sane Ayur Lab has given better returns compared to its competitors. Vaidya Sane Ayur Lab has grown at ~4.08% over the last 3yrs while peers have grown at a median rate of -3.98%
Is the promoter bullish about Vaidya Sane Ayur Lab?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Vaidya Sane Ayur Lab is 66.34% and last quarter promoter holding is 66.34%.
Are mutual funds buying/selling Vaidya Sane Ayur Lab?
There is Insufficient data to gauge this.
